{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T17:40:43Z","timestamp":1762623643038},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.cjca.2015.03.022","type":"journal-article","created":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T19:28:03Z","timestamp":1428434883000},"page":"576-579","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Case Against Using Hypertension as the Only Criterion for Oral Anticoagulation in Atrial Fibrillation"],"prefix":"10.1016","volume":"31","author":[{"given":"Simon W.","family":"Rabkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Moe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2015.03.022_bib1","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib2","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib3","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib4","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2015.03.022_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.cjca.2015.03.022_bib6","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.03.022_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0140-6736(10)60834-3","article-title":"Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study","volume":"376","author":"O'Donnell","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2015.03.022_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.7326\/0003-4819-88-3-342","article-title":"Predicting risk of ischemic heart disease and cerebrovascular disease from systolic and diastolic blood pressures","volume":"88","author":"Rabkin","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2015.03.022_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1161\/01.STR.0000158925.12740.87","article-title":"Blood pressure control and risk of stroke: a population-based prospective cohort study","volume":"36","author":"Liew","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2015.03.022_bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/hrt.2006.099374","article-title":"Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial fibrillation","volume":"93","author":"Varughese","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.cjca.2015.03.022_bib11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1750-3639.2002.tb00450.x","article-title":"Hypertensive cerebral small vessel disease and stroke","volume":"12","author":"Lammie","year":"2002","journal-title":"Brain Pathol"},{"key":"10.1016\/j.cjca.2015.03.022_bib12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.cjca.2015.02.016","article-title":"The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension","volume":"31","author":"Daskalopoulou","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy","volume":"34","author":"Coppens","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jacc.2014.10.052","article-title":"Benefit of anticoagulation unlikely in patients with atrial fibrillation and a CHA2DS2-VASc score of 1","volume":"65","author":"Friberg","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/CIRCOUTCOMES.108.830232","article-title":"Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study","volume":"2","author":"Singer","year":"2009","journal-title":"Circ Qual Outcomes"},{"issue":"12 suppl 1","key":"10.1016\/j.cjca.2015.03.022_bib16","doi-asserted-by":"crossref","first-page":"A362","DOI":"10.1016\/S0735-1097(14)60362-4","article-title":"Poorly controlled blood pressure is independently associated with a 50% higher risk of stroke or systemic embolism in patients with atrial fibrillation: results from the aristotle trial","volume":"63","author":"Rao","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib17","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.03.022_bib18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib19","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.03.022_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib22","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.03.022_bib23","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2015.03.022_bib24","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1161\/01.STR.0000080678.09344.8D","article-title":"Risk factors for intracerebral hemorrhage in the general population: a systematic review","volume":"34","author":"Ariesen","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2015.03.022_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","article-title":"Effect of hypertension on anticoagulated patients with atrial fibrillation","volume":"28","author":"Lip","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2015.03.022_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/hr.2013.25","article-title":"Association among blood pressure control in elderly patients with hypertension, left atrial structure and function and new-onset atrial fibrillation: a prospective 2-year study in 234 patients","volume":"36","author":"Watanabe","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.cjca.2015.03.022_bib27","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/STROKEAHA.113.002585","article-title":"Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation","volume":"45","author":"Aakre","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2015.03.022_bib28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","article-title":"Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry","volume":"170","author":"Ruff","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2015.03.022_bib29","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1161\/STROKEAHA.114.006025","article-title":"Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48","volume":"45","author":"Giugliano","year":"2014","journal-title":"Stroke"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15002111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X15002111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T07:43:36Z","timestamp":1717832616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X15002111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0828282X15002111"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2015.03.022","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Case Against Using Hypertension as the Only Criterion for Oral Anticoagulation in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2015.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}